Skip to main content

Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis

Chan, Jeffrey S. K., Tang, Pias, Hui, Jeremy M. Ho, Lee, Yan H. A., Dee, Edward C., Ng, Kenrick, Liu, Kang, Tse, Gary, Ng, Chi Fai (2022) Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis. The Prostate, 82 (15). pp. 1477-1480. ISSN 0270-4137. E-ISSN 1097-0045. (doi:10.1002/pros.24423) (KAR id:98710)

PDF Publisher pdf
Language: English


Download (495kB) Preview
[thumbnail of The Prostate - 2022 - Chan - Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular.pdf]
Preview
This file may not be suitable for users of assistive technology.
Request an accessible format
Official URL:
https://doi.org/10.1002/pros.24423

Abstract

Background

Although androgen deprivation therapy has known cardiovascular risks, it is unclear if its duration is related to cardiovascular risks. This study thus aimed to investigate the associations between gonadotrophin-releasing hormone (GnRH) agonist use duration and cardiovascular risks.

Methods

This retrospective cohort study included adult patients with prostate cancer receiving GnRH agonists in Hong Kong during 1999–2021. Patients who switched to GnRH antagonists, underwent bilateral orchidectomy, had <6 months of GnRH agonist, prior myocardial infarction (MI), or prior stroke was excluded. All patients were followed up until September 2021 for a composite endpoint of MI and stroke. Multivariable competing-risk regression using the Fine-Gray subdistribution model was used, with mortality from any cause as the competing event.

Results

In total, 4038 patients were analyzed (median age 74.9 years old, interquartile range (IQR) 68.7–80.8 years old). Over a median follow-up of 4.1 years (IQR 2.1–7.5 years), longer GnRH agonists use was associated with higher risk of the endpoint (sub-hazard ratio per year 1.04 [1.01–1.06], p = 0.001), with those using GnRH agonists for ≥2 years having an estimated 23% increase in the sub-hazard of the endpoint (sub-hazard ratio 1.23 [1.04–1.46], p = 0.017).

Conclusion

Longer GnRH agonist use may be associated with greater cardiovascular risks.

Item Type: Article
DOI/Identification number: 10.1002/pros.24423
Uncontrolled keywords: androgen deprivation therapy; cardio‐oncology; cohort; prostate cancer
Subjects: R Medicine > R Medicine (General)
Divisions: Divisions > Division of Natural Sciences > Kent and Medway Medical School
Funders: University of Kent (https://ror.org/00xkeyj56)
Depositing User: Manfred Gschwandtner
Date Deposited: 05 Dec 2022 18:14 UTC
Last Modified: 13 Dec 2022 11:14 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/98710 (The current URI for this page, for reference purposes)
Tse, Gary: https://orcid.org/0000-0001-5510-1253
  • Depositors only (login required):

Downloads

Downloads per month over past year